Personalis, Inc.
NASDAQ:PSNLMedical - Diagnostics & Research
+$0.34 today
- Market cap
- $1.62B
- Beta
- 2.28
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$0.92
Volume 1.47M
Average 2.31M
PSNL Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Personalis, Inc.NASDAQ: PSNL
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $14.54M rose 15.0% year over year, ahead of the +6.9% change in trailing-twelve-month research & development. Sequentially, it rose 11.2% from the prior quarter. Over 3 fiscal years it compounded at -8.2% a year.
Context
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +15.0% holds above the trailing-twelve-month pace of +6.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 50.26M USD
- Year-over-year change
- +2.8%
- 4-year CAGR
- +0.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 50.26M | +2.8% |
| FY2024 | 2024-12-31 | 48.91M | -24.5% |
| FY2023 | 2023-12-31 | 64.78M | -0.2% |
| FY2022 | 2022-12-31 | 64.91M | +31.6% |
| FY2021 | 2021-12-31 | 49.31M | — |
Research & Development vs competitors
How PSNL compares with its peers on the latest reported figures
- PSNL's LTM Mar 2026 research & development of $52.16M is the 9th highest of the 10 companies compared; the peer median is $93.37M.
- Its year-over-year change of +6.9% is the 8th highest of 10, against a peer median of +11.9%.
- Research & development amounts to 80.9% of revenue for PSNL, versus a peer median of 17.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $787.38M | +56.9% | +25.4% | 29.1% | |
| LTM Sep 2026 | $386.67M | +7.6% | -0.9% | 30.2% | |
| LTM Jun 2026 | $190.99M | -15.8% | -15.9% | 115.6% | |
| LTM Mar 2026 | $106.4M | -7.7% | +7.7% | 12.8% | |
| LTM Jun 2026 | $93.37M | +31.8% | +20.4% | 16.6% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $83.32M | +64.3% | -5.8% | 18.3% |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $59.21M | +38.6% | — | 14.9% |
| LTM Mar 2026 | $55.69M | +11.9% | +23.1% | 17.4% | |
| LTM Mar 2026 | $52.16M | +6.9% | -8.2% | 80.9% | |
| LTM Jun 2026 | $38.17M | +9.5% | +6.9% | 5.0% | |
| Peer median (excluding PSNL) | $93.37M | +11.9% | +7.3% | 17.4% | |
Competitors are the stored peer set for PSNL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 85.49M | 65.05M | 73.48M | 84.61M | 0 |
| Cost of Revenue | 53.84M | 51.7M | 55.27M | 57.79M | 53.87M |
| Gross Profit | 31.66M | 13.35M | 18.21M | 26.83M | (53.87M) |
| Gross Margin | 37.0% | 20.5% | 24.8% | 31.7% | — |
| Research & Development | 49.31M | 64.91M | 64.78M | 48.91M | 50.26M |
| Selling, General & Admin | 47.7M | 63.97M | 49.73M | 46.19M | 53.57M |
| Operating Expenses | 97.01M | 128.88M | 128.14M | 95.09M | 34.19M |
| Depreciation & Amortization | 6.01M | 8.43M | 11.3M | 10.94M | 10.05M |
| EBITDA | (59.01M) | (104.64M) | (96.81M) | (70.3M) | (71M) |
| EBITDA Margin | -69.0% | -160.9% | -131.7% | -83.1% | — |
| Operating Income | (65.35M) | (115.53M) | (109.94M) | (68.27M) | (88.06M) |
| Operating Margin | -76.4% | -177.6% | -149.6% | -80.7% | — |
| Interest Income | 367K | 2.4M | 5.9M | 5.51M | 7.16M |
| Interest Expense | 184K | 201K | 110K | 24K | 205K |
| Other Income / Expenses | 141K | 2.26M | 1.72M | (13M) | 6.81M |
| Income Before Tax | (65.21M) | (113.28M) | (108.21M) | (81.27M) | (81.25M) |
| Pre-Tax Margin | -76.3% | -174.1% | -147.3% | -96.0% | — |
| Income Tax Expense | 14K | 40K | 83K | 18K | 21K |
| Net Income | (65.23M) | (113.32M) | (108.3M) | (81.28M) | (81.27M) |
| Net Margin | -76.3% | -174.2% | -147.4% | -96.1% | — |
| EPS (Basic) | (1.49) | (2.48) | (2.25) | (1.37) | (0.91) |
| EPS (Diluted) | (1.49) | (2.48) | (2.25) | (1.37) | (0.91) |
| Weighted Avg Shares | 43.89M | 45.7M | 48.18M | 59.25M | 89.24M |
| Weighted Avg Shares (Diluted) | 43.89M | 45.7M | 48.18M | 59.25M | 89.24M |
Personalis, Inc.
NASDAQ:PSNL
Intrinsic Alpha fair value
Locked
Current Price
$14.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.